Literature DB >> 29684235

Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Douglas Tremblay, Kelsey Sokol, Sheena Bhalla, Raajit Rampal, John O Mascarenhas.   

Abstract

The advent of high-throughput gene sequencing has revolutionized our understanding of the genetic mutations that drive myeloid malignancies. While these mutations are of interest pathobiologically, they are increasingly being recognized as clinically meaningful in providing diagnostic, prognostic, and therapeutic information to guide patient care. In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies. Next, we discuss the diagnostic and prognostic role of mutation profiling in myelodysplastic syndrome and acute myeloid leukemia. Finally, we detail the therapeutic implications of specific mutations in myelodysplastic syndrome and acute myeloid leukemia. In Part 2, we will discuss similar clinical approaches using mutation profiling in myeloproliferative neoplasms and other myeloid malignancies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29684235

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

Review 1.  Novel therapeutic strategy based on genetic and epigenetic abnormalities for myeloid neoplasms.

Authors:  Takahiro Yamauchi
Journal:  Int J Clin Oncol       Date:  2019-05-18       Impact factor: 3.402

2.  Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.

Authors:  Geetanjali R Kamath; Douglas Tremblay; Alexander Coltoff; Jessica Caro; Guido Lancman; Sheena Bhalla; Vesna Najfeld; John Mascarenhas; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-07-04       Impact factor: 4.944

3.  Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms.

Authors:  Graeme Greenfield; Suzanne McPherson; James Smith; Adam Mead; Claire Harrison; Ken Mills; Mary Frances McMullin
Journal:  Cancers (Basel)       Date:  2020-09-18       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.